NMS-03305293
Phase 2Small molecule
NMS-03305293 is one of 139 small molecule programs targeting Ovarian Cancer. It is currently in Phase 2.
3
Indications
4
Total Trials
3
Active Trials
138
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
209 competitors in Ovarian Cancer
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Gemzar
Johnson & JohnsonPhase 3
Pegylated Liposomal Doxorubicin
Merck & Co.Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Trodelvy
GileadPhase 3
Lynparza
RRisen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
Neulasta
AmgenPhase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Afinitor
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced/Metastatic Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NMS-03305293. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNerviano Medical Sciences